Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery to Support Blueprint Medicines' Cancer Research Platform

NEW YORK (GenomeWeb News) – Horizon Discovery announced today a research service agreement to deploy its X-MAN isogenic cell lines in support of Blueprint Medicine's "New Targets" discovery platform.

Blueprint is based in Cambridge, Mass., and develops highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will use its platform and expertise to screen certain Blueprint kinase inhibitor tool compounds on a panel of 26 X-MAN isogenic cell lines, in the process providing insights into "elucidating synthetic lethal interactions with approximately 100 kinase targets in various cancer subtypes."

Blueprint has developed a platform combining genomics expertise with a novel library of kinase inhibitors that allows the development of "potent, highly selective compounds to address clear genomic driver targets," Horizon said.

Financial and other terms were not disclosed.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.